Danel (Adir Yeoshua) Ltd. (IL:DANE)
TASE:DANE
Want to see IL:DANE full AI Analyst Report?
Top Page
Danel
(TASE:DANE)
Select Model
Select Model
Rating:63Neutral
Price Target:
49,118.00
▲(5.79% Upside)
Action:Reiterated
Date:05/21/26
The score is supported primarily by improving financial performance (strong revenue rebound, restored profitability, and positive free cash flow) and a decent dividend yield, but it is held back by neutral-to-weak technical momentum (negative MACD) and a relatively expensive P/E multiple, with leverage still a watch item.
Positive Factors
Revenue Momentum
Very strong trailing-twelve-month revenue growth paired with restored EBIT and net margins indicates durable demand and successful operational recovery. For a service-based care provider this signals expanding market penetration and better utilization of fixed overheads, supporting sustainable cash generation.
Negative Factors
Cash Conversion
Free cash flow at ~62% of net income and a low operating cash flow coverage ratio imply earnings are not fully converting to cash. That gap can constrain the pace of deleveraging, dividend reliability and discretionary spending, leaving sensitivity to working-capital swings and billing/timing risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Momentum
Very strong trailing-twelve-month revenue growth paired with restored EBIT and net margins indicates durable demand and successful operational recovery. For a service-based care provider this signals expanding market penetration and better utilization of fixed overheads, supporting sustainable cash generation.
Read all positive factors
Danel (DANE) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪2.81B
Dividend Yield2.98%
Average Volume (3M)11.82K
Price to Earnings (P/E)22.2
Beta (1Y)0.85
Revenue Growth4.37%
EPS Growth396.88%
CountryIL
Employees4,290
SectorConsumer Defensive
Sector Strength42
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)21.80
Shares Outstanding5,964,005
10 Day Avg. Volume13,517
30 Day Avg. Volume11,824
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)5.35
Price to Sales (P/S)0.94
P/FCF Ratio18.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Danel Business Overview & Revenue Model
Company Description
Operating in Israel, Danel (Adir Yeoshua) Ltd specializes in delivering a comprehensive suite of human resource solutions. The firm's core offerings encompass talent acquisition (recruitment and placement), payroll administration, and project over...
How the Company Makes Money
Danel makes money mainly by delivering care-related services and receiving service fees for providing and managing those services. A key revenue stream is nursing/home-care: the company supplies caregivers and care programs and is paid for the pro...
Danel Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
68
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.93B | 2.90B | 2.77B | 2.51B | 2.36B | 2.29B |
| Gross Profit | 527.10M | 492.05M | 510.71M | 458.31M | 464.44M | 492.51M |
| EBITDA | 307.95M | 304.07M | 223.61M | 84.01M | 206.17M | 283.44M |
| Net Income | 126.77M | 116.95M | 20.51M | -11.22M | 115.79M | 174.15M |
Balance Sheet | ||||||
| Total Assets | 1.38B | 1.42B | 1.31B | 1.30B | 1.27B | 1.13B |
| Cash, Cash Equivalents and Short-Term Investments | 215.45M | 213.43M | 251.20M | 185.15M | 139.98M | 81.09M |
| Total Debt | 325.62M | 326.89M | 363.56M | 376.07M | 335.48M | 262.58M |
| Total Liabilities | 847.95M | 907.58M | 853.41M | 816.38M | 758.19M | 729.68M |
| Stockholders Equity | 529.10M | 507.56M | 452.26M | 471.44M | 493.17M | 364.45M |
Cash Flow | ||||||
| Free Cash Flow | 161.10M | 143.06M | 187.65M | 156.91M | 141.66M | 180.19M |
| Operating Cash Flow | 259.05M | 235.81M | 223.06M | 206.72M | 205.71M | 231.64M |
| Investing Cash Flow | -103.17M | -96.30M | -34.05M | -73.82M | -79.02M | -124.25M |
| Financing Cash Flow | -159.05M | -177.29M | -122.96M | -87.73M | -67.80M | -167.71M |
Danel Technical Analysis
Positive
46430.00
Price Trends
46186.63
Positive
45502.97
Positive
45976.13
Positive
Market Momentum
428.59
Negative
57.44
Neutral
54.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:DANE, the sentiment is Positive. The current price of 46430 is below the 20-day moving average (MA) of 46954.38, above the 50-day MA of 46186.63, and above the 200-day MA of 45976.13, indicating a bullish trend. The MACD of 428.59 indicates Negative momentum. The RSI at 57.44 is Neutral, neither overbought nor oversold. The STOCH value of 54.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IL:DANE.
Danel Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₪729.98M | 13.17 | ― | ― | 6.51% | 28.39% | |
66 Neutral | ₪5.05B | 22.53 | ― | 4.01% | 8.36% | -3.54% | |
63 Neutral | ₪2.81B | 22.16 | ― | 2.98% | 4.37% | 396.88% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
59 Neutral | ₪1.28B | 15.36 | ― | 1.69% | 15.35% | 41.29% | |
51 Neutral | ₪408.70M | 115.33 | ― | 3.05% | -13.68% | -87.66% |
* Consumer Defensive Sector Average
IL:DANE
Danel
47,580.00
5,943.78
14.28%
IL:DIPL
Diplomat Holdi.
5,004.00
824.10
19.72%
IL:TTAM
Tiv Taam
1,203.00
434.71
56.58%
IL:WLFD
Willy Food
5,535.00
2,142.00
63.13%
IL:RMLI
Rami Levi
36,640.00
5,817.42
18.87%
IL:NVLG
Novolog
80.00
-56.98
-41.60%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.